The acquisition has been valued at an enterprise value of about ₹91 crore. Of this, around ₹76 crore comprises total debt and expected liabilities related to the manufacturing plant that will be taken over by Senores Pharmaceuticals, while the remaining about ₹15 crore will be paid in cash. Shares of Senores Pharmaceuticals Ltd ended at ₹817.00, up by ₹30.90, or 3.93%, on the BSE.
